Developmental stage biopharmaceutical company specializing on integrating traditional therapeutics with psychedelics to treat various mental conditions Silo Pharma Inc. (OTCMKTS: SILO) announced having submitted a study in which psilocybin is used to treat Parkinson’s disease for ethics board review in the Netherlands.
“We are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders,” said the company’s CEO Eric Weisblum.
